menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Testing Your Ovarian Cancer Patients for Homologous Recombination Deficiency

5 chapters
Play All
Details
Chapters
Recommended

Overview

Chapter 1
ReachMD Healthcare Image
RestartResume

In this five-part series, experts discuss why and how you should test for homologous recombination deficiency (HRD) in patients with advanced ovarian cancer.

  • Sponsored by

  • Overview

    Knowing the homologous recombination deficiency (HRD) status of advanced ovarian cancer patients can provide key prognostic information and guide important treatment decisions. That’s why this five-part series features a panel of experts who discuss the practical aspects of genomic testing in advanced ovarian cancer care, including its purpose, how to successfully implement testing in clinical practice, and how to communicate the value of HRD testing to patients. The panel includes Drs John Nakayama, Alexander Olawaiye, and Joshua Kesterson.

    ©2023 AstraZeneca. All rights reserved. US-81081 Last Updated 11/23

Schedule28 Feb 2024